COPD accounts for approximately 12 to 15 per cent of the SCE Respiratory exam. The GOLD (Global Initiative for Chronic Obstructive Lung Disease) Report is the international reference for COPD classification and pharmacotherapy, supplemented by NICE NG115 for UK-specific management pathways. This page covers the high-yield content from the current GOLD report.
Classification
GOLD classifies COPD severity using two axes: spirometric severity (GOLD 1 to 4 based on post-bronchodilator FEV1 as a percentage of predicted) and symptom burden plus exacerbation history (groups A, B, and E — the former groups C and D were merged into group E in the 2023 revision).
Spirometric grades: GOLD 1 (FEV1 80 per cent or above predicted, mild), GOLD 2 (50 to 79 per cent, moderate), GOLD 3 (30 to 49 per cent, severe), GOLD 4 (below 30 per cent, very severe). All require FEV1/FVC below 0.7 post-bronchodilator to confirm airflow obstruction.
Symptom groups: Group A (low symptoms measured by mMRC 0 to 1 or CAT below 10, 0 to 1 exacerbations per year not leading to hospitalisation), Group B (higher symptoms with mMRC 2 or more or CAT 10 or above, 0 to 1 exacerbations not leading to hospitalisation), Group E (exacerbation history — 2 or more moderate exacerbations or 1 or more leading to hospitalisation, regardless of symptom burden).
The exam tests whether you can classify a patient using both axes and select the appropriate initial pharmacotherapy based on their group.
Pharmacological management
Group A: a short-acting bronchodilator (SABA or SAMA) as needed. No regular maintenance therapy required.
Group B: a long-acting bronchodilator — either a LABA (salmeterol, formoterol, indacaterol, olodaterol) or a LAMA (tiotropium, umeclidinium, glycopyrronium). If symptoms persist, escalate to LABA plus LAMA combination. GOLD now recommends LABA plus LAMA as the preferred combination rather than LABA plus ICS, because LABA plus LAMA provides superior bronchodilation without the pneumonia risk associated with ICS.
Group E: LABA plus LAMA is the recommended initial therapy. If blood eosinophils are 300 cells per microlitre or above, consider LABA plus LAMA plus ICS (triple therapy) from the outset. If eosinophils are below 300, start with LABA plus LAMA and only add ICS if exacerbations continue despite dual bronchodilation and eosinophils are 100 or above.
The eosinophil-guided ICS prescribing is a critical exam topic. The old approach of adding ICS to any patient with frequent exacerbations has been replaced by a biomarker-guided strategy. ICS benefit is concentrated in patients with eosinophils 300 or above; patients with eosinophils below 100 derive minimal benefit and face increased pneumonia risk. The 100 to 300 range is a grey zone where clinical judgement applies.
Exacerbation management
Acute COPD exacerbation management follows a standardised approach: increased short-acting bronchodilator use, oral prednisolone 30 mg daily for 5 days (NICE recommends 5 days; GOLD allows up to 5 to 7 days), antibiotics if purulent sputum or signs of bacterial infection (amoxicillin, doxycycline, or clarithromycin), and controlled oxygen therapy targeting SpO2 88 to 92 per cent (to avoid CO2 retention in patients with type 2 respiratory failure).
NIV (non-invasive ventilation) is indicated for acute hypercapnic respiratory failure (pH below 7.35 with PaCO2 above 6.0 kPa) despite optimal medical therapy including controlled oxygen. NIV should be initiated within one hour of the blood gas confirming the indication. The exam tests the specific pH and PaCO2 thresholds for NIV initiation.
Long-term oxygen therapy
LTOT is indicated for patients with stable COPD who have a PaO2 at or below 7.3 kPa when breathing air on two occasions at least three weeks apart, or a PaO2 of 7.3 to 8.0 kPa with evidence of secondary polycythaemia (haematocrit above 0.55), pulmonary hypertension, or peripheral oedema.
LTOT must be used for at least 15 hours per day to confer survival benefit. Patients must not smoke while on oxygen (fire risk). Assessment should be performed during a period of clinical stability, not during or shortly after an exacerbation.
The exam tests the PaO2 thresholds (7.3 kPa and 7.3 to 8.0 kPa with complications) and the 15-hour minimum usage requirement.
Smoking cessation
Smoking cessation is the single most effective intervention for slowing COPD progression. The exam may test pharmacological smoking cessation aids — nicotine replacement therapy, varenicline (the most effective single agent), and bupropion. All COPD patients who smoke should be offered smoking cessation support at every clinical contact.
iatroX's SCE Respiratory bank includes comprehensive COPD content aligned to the current GOLD report and NICE NG115. Classification, pharmacotherapy group allocation, eosinophil-guided ICS prescribing, exacerbation management, NIV thresholds, and LTOT criteria are all covered. All included at £29 per month or £99 per year.